Sedative–Hypnotics: Pharmacology, Dosing, Dependence and Safe Prescribing
On this page
01
Overview
Sedative–hypnotics depress the central nervous system to reduce anxiety and induce or maintain sleep. They span several pharmacological families — benzodiazepines, Z-drugs, barbiturates, melatonin agonists, orexin antagonists and sedating antihistamines — that differ greatly in selectivity, safety margin, dependence liability and clinical use. These are among the most prescribed and most misused drugs in medicine: they are valuable for short-term insomnia, anxiety, seizures, alcohol withdrawal and procedural sedation, but all carry risks of tolerance, dependence, falls, cognitive impairment and dangerous respiratory depression in combination with alcohol or opioids.
Prescribe the lowest effective dose for the shortest possible time, avoid combining sedatives, and always plan the exit strategy — how and when the drug will be stopped — before the first prescription is written.
02
Learning objectives
- Compare the major sedative–hypnotic classes by mechanism, onset, duration and safety margin.
- State adult and paediatric doses, indications and key cautions for the common agents.
- Explain tolerance, dependence and the benzodiazepine withdrawal syndrome, and design a taper.
- Manage benzodiazepine overdose and understand the limits of flumazenil.
- Apply safe-prescribing principles in the elderly, pregnancy, liver disease and children.
03
Sleep and insomnia
Sleep cycles between non-REM (restorative, slow-wave) and REM (dreaming) stages. Benzodiazepines and Z-drugs shorten sleep-onset latency but suppress slow-wave and REM sleep, which is why they produce unrefreshing sleep and can cause rebound phenomena on stopping. Insomnia lasting under 3 months (acute) often responds to sleep-hygiene measures alone; chronic insomnia is managed first with cognitive behavioural therapy for insomnia (CBT-I), with drugs reserved for short-term or adjunctive use.
- Sleep hygiene: fixed wake time, no daytime naps, no caffeine after midday, no screens in bed, bed only for sleep.
- Drug principle: treat the cause (pain, depression, alcohol, stimulants, obstructive sleep apnoea) before sedating the symptom.
04
Drug classes
Scroll the table sideways on a smaller screen.
| Class | Mechanism | Examples | Main uses | Key risks |
|---|---|---|---|---|
| Benzodiazepines | Positive allosteric modulators of GABA-A receptors | Diazepam, lorazepam, temazepam, alprazolam, clonazepam, midazolam | Anxiety, insomnia, seizures, alcohol withdrawal, muscle spasm, sedation | Dependence, falls, respiratory depression with opioids/alcohol, amnesia |
| Z-drugs | GABA-A modulators selective for omega-1 (BZ1) receptors | Zolpidem, zopiclone, zaleplon | Short-term insomnia | Less anxiolytic/anticonvulsant; complex sleep behaviours (sleep-walking, driving), dependence |
| Barbiturates | Direct GABA-A agonists (also block glutamate) | Phenobarbital, thiopental | Neonatal seizures, status (thiopental), anaesthesia | Narrow safety margin, severe respiratory depression, enzyme induction, dangerous overdose |
| Melatonin agonists | MT1/MT2 receptor agonism resetting circadian rhythm | Melatonin, ramelteon | Insomnia, jet lag, paediatric sleep problems | Mild; drowsiness, headache |
| Orexin antagonists | Block orexin-mediated wakefulness | Suvorexant | Chronic insomnia | Somnolence, sleep paralysis; limited availability |
| Sedating antihistamines | Central H1 blockade | Promethazine, hydroxyzine | Short-term insomnia, allergy, nausea | Anticholinergic effects — avoid in elderly and glaucoma/prostate disease |
05
Benzodiazepines
Benzodiazepines increase the frequency of GABA-A chloride-channel opening, hyperpolarising neurons and producing anxiolysis, sedation, anticonvulsant activity, muscle relaxation and anterograde amnesia. They do not activate the receptor directly, which is why they are safer than barbiturates — but they are still dangerous in overdose and in combination with other depressants.
Scroll the table sideways on a smaller screen.
| Drug | Adult dose | Paediatric notes | Main adverse effects | Contraindications / interactions |
|---|---|---|---|---|
| Diazepam (long-acting) | Anxiety 2 mg TDS; muscle spasm 2–15 mg/day; status 10–20 mg IV/PR | Status: 0.2–0.5 mg/kg PR | Sedation, dependence with regular use, accumulation in the elderly and liver disease | Avoid in sleep apnoea, severe respiratory failure, myasthenia gravis; potentiates alcohol, opioids, other sedatives |
| Lorazepam (intermediate) | Anxiety 1–4 mg/day in divided doses; status 4 mg IV | Status: 0.05–0.1 mg/kg IV | Sedation, ataxia, falls in the elderly | Preferred in liver disease (no active metabolites); same interaction profile as diazepam |
| Temazepam (hypnotic) | Insomnia 10–20 mg at night (elderly: 5–10 mg) | Not recommended for children | Morning hangover, amnesia | Short courses only (days–2 weeks) because of dependence |
| Alprazolam | Anxiety/panic 0.25–0.5 mg TDS | Not recommended | High dependence and abuse liability, difficult withdrawal | Avoid long-term; cross-taper slowly |
06
Z-drugs
Zolpidem and zopiclone preferentially bind the omega-1 (BZ1) subtype of the GABA-A receptor, giving sedation with less anxiolytic and anticonvulsant effect. They are useful for short-term insomnia but are not dependence-free — tolerance and rebound insomnia occur within weeks, and complex sleep behaviours (sleep-walking, sleep-eating, even sleep-driving) are a recognised warning sign to stop the drug.
Scroll the table sideways on a smaller screen.
| Drug | Adult dose | Elderly / hepatic | Adverse effects | Interactions |
|---|---|---|---|---|
| Zolpidem | 5–10 mg at night immediately before bed (10 mg max) | 5 mg; avoid in severe liver disease | Bitter/metallic taste rare; amnesia, complex sleep behaviours, next-day impairment | CYP3A4 inhibitors (azoles, ritonavir) raise levels |
| Zopiclone | 3.75–7.5 mg at night | 3.75 mg in elderly or liver impairment | Bitter metallic taste (very common), nausea, dependence | CYP3A4 inhibitors; additive with alcohol and opioids |
07
Other agents
Scroll the table sideways on a smaller screen.
| Drug | Dose | Indication | Adverse effects / cautions |
|---|---|---|---|
| Melatonin | 2–5 mg 30–60 min before sleep; 0.5–5 mg in children with sleep-phase disorder under specialist guidance | Insomnia (especially sleep-phase delay), jet lag, children with neurodevelopmental sleep problems | Drowsiness, headache, vivid dreams; caution in epilepsy |
| Phenobarbital | Loading 20 mg/kg IV/IM for neonatal seizures; maintenance 3–5 mg/kg/day | Neonatal seizures; second-line for other seizures where cheaper agents unavailable | Sedation, hypotension, enzyme induction (reduces efficacy of many drugs); narrow margin |
| Promethazine | 25 mg at night for short-term insomnia | Short-term sedation, allergy, nausea | Anticholinergic — dry mouth, urinary retention, confusion; avoid in elderly, glaucoma, prostatic hypertrophy |
| Chloral hydrate (historical) | Previously used for paediatric sedation | Largely replaced by melatonin and better agents | Gastric irritation, arrhythmia risk with overdose — know it for exams, rarely use it in practice |
08
Dependence, withdrawal and tapering
With regular use the brain compensates for constant GABA enhancement by down-regulating receptors. Stopping suddenly then produces withdrawal: anxiety, insomnia, tremor, sweating, and in severe cases seizures and delirium — which can be fatal. Short-acting agents (alprazolam, lorazepam, temazepam) cause earlier and sharper withdrawal than long-acting diazepam.
Tapering principle: switch to a long-acting agent (diazepam) if needed, then reduce the dose slowly — typically by about 10–25% every 1–2 weeks, slower at the low-dose end. A rough guide for diazepam: 10 mg → 5 mg → 2.5 mg → 1 mg → stop, spending 1–2 weeks at each step. Never stop a regular benzodiazepine abruptly after weeks of use.
09
Overdose and flumazenil
Benzodiazepine overdose causes drowsiness, slurred speech, ataxia and, in significant overdose, respiratory depression — but isolated benzodiazepine overdose is rarely fatal. The danger is mixed overdose with opioids, alcohol or tricyclics. Management is supportive: airway, breathing, circulation, observation.
Flumazenil is a competitive GABA-A antagonist that reverses sedation, but its use is limited: it can precipitate seizures in patients on long-term benzodiazepines, in mixed overdoses (especially with pro-convulsants) and in chronic alcohol dependence. It is therefore reserved for iatrogenic over-sedation (e.g., after procedural sedation) rather than street overdose.
10
Special populations
- Elderly: increased sensitivity, slower metabolism of diazepam, and falls with hip fracture — use the lowest doses (temazepam 5–10 mg), shortest courses, prefer lorazepam or oxazepam if a benzodiazepine is unavoidable.
- Pregnancy: neonatal withdrawal and floppy-infant syndrome with regular use near delivery; avoid unless clearly indicated.
- Liver disease: diazepam accumulates — prefer lorazepam or oxazepam, which are metabolised by conjugation.
- Children: avoid routine hypnotics; melatonin and behavioural measures are preferred for sleep problems.
- Respiratory disease: avoid in obstructive sleep apnoea and severe COPD/respiratory failure — sedatives blunt the hypoxic drive.
11
Clinical scenarios
Scenario 1 — Insomnia consultation (OSCE)
A 38-year-old teacher has had 6 weeks of poor sleep since her mother’s illness. She asks for “sleeping tablets”. Correct response: explore duration, caffeine, screens, stress and low mood; advise sleep hygiene and CBT-I; if a drug is used at all, offer the shortest possible course (e.g., zopiclone 3.75–7.5 mg for 3–5 nights) with a clear stop date, and warn against combining with alcohol. Long-term hypnotic prescribing without addressing the cause is the classic exam error.
Scenario 2 — Found unresponsive
A man is brought in drowsy with slow respirations; an empty bottle of his partner’s diazepam is nearby, and he smells of alcohol. Support airway and breathing first; give flumazenil only if sedation is iatrogenic and he is not a chronic user — in a mixed overdose with alcohol, flumazenil risks seizures. Observe at least 4–6 hours; diazepam’s long half-life means deterioration can be delayed.
Scenario 3 — Alcohol withdrawal
A 52-year-old man admitted after a fall trembles, sweats and is tachycardic 12 hours after his last drink. Prescribe a benzodiazepine taper — e.g., chlordiazepoxide 25 mg QDS days 1–2, 25 mg BD day 3, 25 mg nocte day 4, then stop — plus oral thiamine 100–200 mg daily. Escalate the taper if withdrawal worsens; use oral diazepam 10–20 mg where chlordiazepoxide is unavailable.
12
Key points
13
References
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics (Library reference.)
- Rang & Dale’s Pharmacology (Library reference.)
- British National Formulary (BNF) — drug doses and cautions (Library reference.)
- Lippincott Illustrated Reviews: Pharmacology (Library reference.)
14
Further reading
For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.
For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.